Abstract
INTEREST IN extracorporeal membrane oxygenation (ECMO) for treating severe respiratory failure in adults has increased substantially in the last 5 years. There are several reasons for this increase. The first reason is the publication of the CESAR study in 2009, which showed improved survival in adults with severe acute respiratory distress syndrome (ARDS) randomized to consideration of ECMO compared with patients treated conventionally.1 Second is the H1N1 influenza pandemic of 2009 and 2010, which resulted in a substantial increase in the use of ECMO for treating severe respiratory failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
